DENVER–(BUSINESS WIRE)–June 6, 2022–
VieCure, a cancer care company, today announced at ASCO 2022 the release of its next-generation oncology clinical decision support platform, including the introduction of Halo Intelligence for oncologists . The reality of cancer medicine today is the ever-increasing complexity of diagnosis, treatment and follow-up care. “In the 1980s, medical data and evidence doubled every 7 years, but by 2020 it will double every 73 days,” says Dr. Fred Ashbury, PhD and Chief Scientific Officer of VieCure. “Annual FDA cancer drug approvals increased 200% between 2010 and 2020.”
This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220606005818/en/
Halo Intelligence, from VieCure, is the first comprehensive oncology knowledge system that brings together everything clinicians need to find the right treatment path for every patient, every time. (Photo: BusinessWire)
There are also interrelated challenges. ASCO predicts a shortage of about 2,250 oncologists by 2025 and oncologists and clinicians should read up to 29 hours a day to stay current and up to date with the latest clinical trials and new therapies. VieCure recognized that the traditional electronic medical record system in oncology simply could not meet the needs of oncologists, nurses, pharmacists, therapists and patients in the 2020s. They created the VieCure™ platform, which includes a proprietary artificial intelligence clinical inference engine and oncology point-of-care decision support system. The platform is designed to create and implement unique, patient-specific treatment plans. The platform includes a complete ecosystem of tools, including the oncology information management system, mobile application for patients, mobile application for doctors, an attached codified content library, integrated telehealth and a system sophisticated analysis.
VieCure has now added Halo Intelligence to the platform. At the heart of VieCure is exciting new technology that is unlike anything currently available on the market today. It’s a new way to support patients, a new way to superpower clinicians, and a new category that we need to establish. But making Halo Intelligence a reality starts with a better understanding of what it is and how we should talk about it.
What is that.
Halo Intelligence is the first comprehensive knowledge system that brings together everything clinicians need to find the right treatment path for every patient, every time. It does this by distilling data from multiple sources using an AI inference engine connected to the VieCure operating ecosystem. The end result is a seamless marriage of artificial intelligence and the clinician’s own natural intelligence, creating what is called Halo Intelligence. Developed exclusively by VieCure, it is designed to change the way the world treats cancer. Because it surrounds clinicians with a ring of knowledge that they can instantly and seamlessly access.
What it is not.
Natural intelligence is the ability of the human mind to process and organize input into actionable knowledge. What makes natural intelligence so powerful is the ability to interpret and react to less rational changes in situation. But we are limited in our ability to process much larger amounts of data. Artificial intelligence is the use of computer systems to simulate and reproduce the functions of the human mind. It has the ability to process much larger amounts of data but lacks the sensitivity and intuition that natural intelligence uses to fully understand the implications of its decisions.
Global understanding of cancer, treatments and patient data has exploded exponentially in recent years – and it shows no signs of slowing down.
This technology allows clinicians to stay one step ahead of this information. Learn more at www.viecure.com or by following VieCure on social media platforms like LinkedIn, Facebook and Twitter.
VieCure has developed a proprietary artificial intelligence computing software platform in conjunction with a clinical inference engine and oncology point-of-care decision support system. The VieCure™ platform combines the latest clinical insights with patient data to help clinicians generate personalized treatment plans and better manage a patient’s treatment throughout diagnosis, cancer treatment and follow-up care continuous. VieCure was launched in 2015 and has contracts with leading community cancer centers like the Center for Cancer and Blood Disorders (Fort Worth, Texas), Alabama Cancer Care (Tuscaloosa, Alabama), Clermont Oncology (Clermont, Florida ), and several others, including the American Oncology Network. The VieCure contract cancer center network now includes more than 100 sites in the United States, Bahamas and Antigua. Active implementation of the VieCure platform is occurring in network locations across the United States. For more information, please visit viecure.com and connect with VieCure on LinkedIn, Facebook and YouTube.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220606005818/en/
CONTACT: VieCure, Inc.
Michael G. Power, Director of Business Development
KEYWORD: COLORADO UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY DATA MANAGEMENT HEALTH TECHNOLOGY SOFTWARE PHARMACEUTICAL BIOTECHNOLOGY
Copyright BusinessWire 2022.
PUBLISHED: 06/06/2022 11:58 AM/DISC: 06/06/2022 11:58 AM